

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 15 CAOLD to be discontinued on December 31, 2008  
NEWS 3 OCT 07 EPFULL enhanced with full implementation of EPC2000  
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent  
number searching  
NEWS 5 OCT 22 Current-awareness alert (SDI) setup and editing  
enhanced  
NEWS 6 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT  
Applications  
NEWS 7 OCT 24 CHEMLIST enhanced with intermediate list of  
pre-registered REACH substances  
NEWS 8 NOV 21 CAS patent coverage to include exemplified prophetic  
substances identified in English-, French-, German-,  
and Japanese-language basic patents from 2004-present  
NEWS 9 NOV 26 MARPAT enhanced with FSORT command  
NEWS 10 NOV 26 MEDLINE year-end processing temporarily halts  
availability of new fully-indexed citations  
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy  
NEWS 12 NOV 26 Two new SET commands increase convenience of STN  
searching  
NEWS 13 DEC 01 ChemPort single article sales feature unavailable  
NEWS 14 DEC 12 GBFULL now offers single source for full-text  
coverage of complete UK patent families  
NEWS 15 DEC 17 Fifty-one pharmaceutical ingredients added to PS  
  
NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 23:10:38 ON 22 DEC 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 23:10:45 ON 22 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 DEC 2008 HIGHEST RN 1088138-51-5

DICTIONARY FILE UPDATES: 21 DEC 2008 HIGHEST RN 1088138-51-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10543109c.str



chain nodes :

7 8 9 10 11 12 13 14 15 24

ring nodes :

1 2 3 4 5 6 16 19 20 21 22 23

chain bonds :

5-7 7-8 8-9 8-10 9-11 11-12 12-13 12-15 13-14 14-16 21-24

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-19 16-23 19-20 20-21 21-22 22-23

exact/norm bonds :

5-7 7-8 8-9 8-10 9-11 12-13 12-15 13-14 21-24

exact bonds :

11-12 14-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-19 16-23 19-20 20-21 21-22 22-23

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 19:Atom 20:Atom  
21:Atom 22:Atom 23:Atom 24:Atom

L1           STRUCTURE UPLOADED

=> s l1 sss full  
FULL SEARCH INITIATED 23:11:00 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED -       26480 TO ITERATE

100.0% PROCESSED       26480 ITERATIONS                   278 ANSWERS  
SEARCH TIME: 00.00.02

L2           278 SEA SSS FUL L1

=> file capl  
COST IN U.S. DOLLARS                                   SINCE FILE       TOTAL  
  ENTRY       SESSION  
FULL ESTIMATED COST                                   178.36       178.57

FILE 'CAPLUS' ENTERED AT 23:11:03 ON 22 DEC 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Dec 2008   VOL 149 ISS 26  
FILE LAST UPDATED: 21 Dec 2008   (20081221/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l2  
L3           17 L2

=> d l3 1-17 ibib hitstr

L3   ANSWER 1 OF 17   CAPLUS   COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER:       2008:830580   CAPLUS  
DOCUMENT NUMBER:       149:153373  
TITLE:                Preparation of substituted amino acid an peptide amide non-nucleoside polymerase alpha and polymerase gamma inhibitors, compositions containing them and methods for treating hyperproliferative diseases  
INVENTOR(S):           Cameron, Dale Russell; Guarna, Maria Marta;  
                          Metlitskaia, Luba  
PATENT ASSIGNEE(S):    Migenix Inc., Can.


SOURCE: PCT Int. Appl., 285pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080223	A1	20080710	WO 2007-CA2367	20071228
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 20080171783 A1 20080717 US 2007-966666 20071228 PRIORITY APPLN. INFO.: US 2006-882541P P 20061228				

OTHER SOURCE(S): MARPAT 149:153373

IT 918435-79-7P, (S)-6-Amino-2-[3-(4-benzyloxyphenyl)ureido]hexanoic acid N-[4-(imidazol-1-yl)phenyl]amide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of substituted amino acid and peptide amides as polymerase alpha and polymerase gamma inhibitors for treating hyperproliferative diseases)  
 RN 918435-79-7 CAPLUS  
 CN Hexanamide, 6-amino-N-[4-(1H-imidazol-1-yl)phenyl]-2-[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:16780 CAPLUS  
 DOCUMENT NUMBER: 146:122298  
 TITLE: Preparation of amino acid amides as non-nucleoside

anti-hepacivirus agents  
 INVENTOR(S): Boyd, Vincent A.; Cameron, Dale R.; Jia, Qi; Sgarbi, Paulo W. M.; Wacowich-Sgarbi, Shirley A.  
 PATENT ASSIGNEE(S): Migenix Inc., Can.  
 SOURCE: PCT Int. Appl., 303pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002639	A2	20070104	WO 2006-US24919	20060626
WO 2007002639	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA CA 2613354 A1 20070104 CA 2006-2613354 20060626 US 20070021434 A1 20070125 US 2006-426580 20060626 EP 1910279 A2 20080416 EP 2006-774070 20060626 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR PRIORITY APPLN. INFO.: US 2005-693569P P 20050624 WO 2006-US24919 W 20060626				

OTHER SOURCE(S): MARPAT 146:122298  
 IT 918435-79-7P, (S)-6-Amino-2-[3-(4-benzyloxyphenyl)ureido]hexanoic acid N-[4-(imidazol-1-yl)phenyl]amide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of amino acid amides as non-nucleoside anti-hepacivirus agents)  
 RN 918435-79-7 CAPLUS  
 CN Hexanamide, 6-amino-N-[4-(1H-imidazol-1-yl)phenyl]-2-[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:1061760 CAPLUS  
 DOCUMENT NUMBER: 146:54689  
 TITLE: Design and evaluation of a novel class-directed 2D  
 fingerprint to search for structurally diverse active  
 compounds  
 AUTHOR(S): Eckert, Hanna; Bajorath, Juergen  
 CORPORATE SOURCE: Department of Life Science Informatics, B-IT,  
 Rheinische Friedrich-Wilhelms-Universitaet, Bonn,  
 D-53113, Germany  
 SOURCE: Journal of Chemical Information and Modeling (2006),  
 46(6), 2515-2526  
 CODEN: JCISD8; ISSN: 1549-9596  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 678178-11-5  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (design and evaluation of class-directed two-dimensional mol.  
 fingerprint to search for structurally diverse active compds.)  
 RN 678178-11-5 CAPLUS  
 CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-  
 N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:558817 CAPLUS  
 DOCUMENT NUMBER: 145:63142  
 TITLE: Preparation of amino acid urea derivatives as factor  
 Xa inhibitors  
 INVENTOR(S): Song, Yonghong; Zhu, Bing-Yan; Wang, Shumei; Bhakta,  
 Chhaya; Scarborough, Robert M.  
 PATENT ASSIGNEE(S): Portola Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 186 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063113	A2	20060615	WO 2005-US44388	20051207
WO 2006063113	A3	20070510		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

US 20060160821 A1 20060720 US 2005-298317 20051207

PRIORITY APPLN. INFO.: US 2004-634201P P 20041207


OTHER SOURCE(S): CASREACT 145:63142; MARPAT 145:63142

IT 891788-33-3P 891788-46-8P 891788-79-7P  
891788-89-9P 891788-90-2P 891788-91-3P  
891788-92-4P 891789-07-4P 891789-14-3P  
891789-60-9P 891789-62-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of amino acid urea derivs. as factor Xa inhibitors)


RN 891788-33-3 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-3,3-dimethyl- (CA INDEX NAME)




RN 891788-46-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-79-7 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891788-89-9 CAPLUS

CN Butanoic acid, 3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-4-oxo-, phenylmethyl ester, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 891788-90-2 CAPLUS

CN Butanoic acid, 3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 891788-91-3 CAPLUS

CN Butanoic acid, 3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-4-oxo-, phenylmethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 891788-92-4 CAPLUS


CN Butanoic acid, 3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-4-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 891789-07-4 CAPLUS

CN Benzeneacetamide, 2-bromo-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891789-14-3 CAPLUS

CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-methyl- (CA INDEX NAME)




RN 891789-60-9 CAPLUS

CN 4-Hexynamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891789-62-1 CAPLUS

CN 4-Pentenamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




IT	891788-31-1P	891788-32-2P	891788-34-4P
	891788-35-5P	891788-36-6P	891788-37-7P
	891788-38-8P	891788-39-9P	891788-40-2P
	891788-41-3P	891788-42-4P	891788-43-5P
	891788-44-6P	891788-47-9P	891788-48-0P
	891788-60-6P	891788-61-7P	891788-62-8P
	891788-70-8P	891788-80-0P	891788-81-1P
	891788-82-2P	891788-88-8P	891788-93-5P
	891788-94-6P	891788-95-7P	891788-96-8P
	891788-97-9P	891788-98-0P	891788-99-1P
	891789-00-7P	891789-01-8P	891789-03-0P
	891789-04-1P	891789-05-2P	891789-06-3P
	891789-08-5P	891789-09-6P	891789-15-4P
	891789-18-7P	891789-22-3P	891789-25-6P
	891789-29-0P	891789-32-5P	891789-36-9P
	891789-37-0P	891789-41-6P	891789-44-9P
	891789-45-0P	891789-49-4P	891789-50-7P
	891789-51-8P	891789-52-9P	891789-53-0P
	891789-54-1P	891789-55-2P	891789-56-3P
	891789-59-6P	891789-61-0P	891789-63-2P
	891789-67-6P	891789-68-7P	891789-70-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid urea derivs. as factor Xa inhibitors)


RN 891788-31-1 CAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891788-32-2 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-3-methyl- (CA INDEX NAME)




RN 891788-34-4 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-4,4-dimethyl- (CA INDEX NAME)



RN 891788-35-5 CAPLUS


CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-36-6 CAPLUS


CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-

N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891788-37-7 CAPLUS

CN 1H-Imidazole-5-propanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891788-38-8 CAPLUS

CN 1H-Indole-3-propanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-1-methyl- (CA INDEX NAME)




RN 891788-39-9 CAPLUS


CN 3-Pyridineacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891788-40-2 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-4-fluoro- (CA INDEX NAME)




RN 891788-41-3 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-fluoro- (CA INDEX NAME)




RN 891788-42-4 CAPLUS  
 CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891788-43-5 CAPLUS  
 CN 3-Thiopheneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891788-44-6 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- $\alpha$ -phenyl- (CA INDEX NAME)



RN 891788-47-9 CAPLUS  
 CN 2-Thiopheneacetamide, N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- $\alpha$ -[[[(4-fluorophenyl)amino]carbonyl]amino]- (CA INDEX NAME)




RN 891788-48-0 CAPLUS  
 CN 2-Thiopheneacetamide, N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- $\alpha$ -[[[(4-ethynylphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 891788-60-6 CAPLUS


CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-bromophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-61-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 891788-62-8 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 891788-70-8 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-bromophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-fluoro- (CA INDEX NAME)




RN 891788-80-0 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(1-oxido-4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 891788-81-1 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)





RN 891788-82-2 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-bromophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)




RN 891788-88-8 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-fluoro- (CA INDEX NAME)

PAGE 1-A







RN 891788-93-5 CAPLUS  
 CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N4,N4-dimethyl- (CA INDEX NAME)



RN 891788-94-6 CAPLUS  
 CN 1-Piperidinebutanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- $\gamma$ -oxo- (CA INDEX NAME)




RN 891788-95-7 CAPLUS  
 CN 4-Morpholinebutanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- $\gamma$ -oxo- (CA INDEX NAME)




RN 891788-96-8 CAPLUS

CN 1-Pyrrolidinebutanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- $\gamma$ -oxo- (CA INDEX NAME)




RN 891788-97-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-1,4-dioxobutyl]-, ethyl ester (CA INDEX NAME)




RN 891788-98-0 CAPLUS

CN 1H-Azepine-1-butanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]hexahydro- $\gamma$ -oxo- (CA INDEX NAME)




RN 891788-99-1 CAPLUS

CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N4-(phenylmethyl)- (CA INDEX NAME)




RN 891789-00-7 CAPLUS

CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N4-methyl- (CA INDEX NAME)




RN 891789-01-8 CAPLUS

CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891789-03-0 CAPLUS

CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N4-phenyl- (CA INDEX NAME)




RN 891789-04-1 CAPLUS

CN Benzeneacetamide, 3-chloro-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891789-05-2 CAPLUS

CN Benzeneacetamide, 2-chloro- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891789-06-3 CAPLUS

CN 1,3-Benzodioxole-5-acetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891789-08-5 CAPLUS

CN Benzeneacetamide, 2-bromo- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-4-pyridinyl)phenyl]- (CA INDEX NAME)




RN 891789-09-6 CAPLUS

CN Benzeneacetamide, 2-bromo- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)




RN 891789-15-4 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-methyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 891789-18-7 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methyl-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)




RN 891789-22-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl]-2-methyl- (CA INDEX NAME)




RN 891789-25-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methyl-N-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 891789-29-0 CAPLUS


CN Benzeneacetamide, 2-chloro- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)






RN 891789-32-5 CAPLUS

CN Benzeneacetamide, 2-chloro- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl]- (CA INDEX NAME)




RN 891789-36-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-methoxy- (CA INDEX NAME)




RN 891789-37-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methoxy-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)




RN 891789-41-6 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl]-2-methoxy- (CA INDEX NAME)




RN 891789-44-9 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-iodo- (CA INDEX NAME)




RN 891789-45-0 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-iodo-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)




RN 891789-49-4 CAPLUS  
 CN Benzeneacetamide, 4-bromo- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891789-50-7 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 891789-51-8 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)




RN 891789-52-9 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-[(trifluoromethyl)thio]- (CA INDEX NAME)




RN 891789-53-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]-2-[(trifluoromethyl)thio]- (CA INDEX NAME)




RN 891789-54-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-phenoxy- (CA INDEX NAME)




RN 891789-55-2 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]-2-phenoxy- (CA INDEX NAME)




RN 891789-56-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-(methylthio)-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)




RN 891789-59-6 CAPLUS

CN 4-Pentynamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 891789-61-0 CAPLUS

CN 4-Hexynamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-63-2 CAPLUS


CN 4-Pentenamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-67-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 891789-68-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 891789-70-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:505914 CAPLUS

DOCUMENT NUMBER: 145:95784

TITLE: The discovery of glycine and related amino acid-based factor Xa inhibitors

AUTHOR(S): Kohrt, Jeffrey T.; Filipinski, Kevin J.; Cody, Wayne L.; Bigge, Christopher F.; La, Frances; Welch, Kathleen; Dahring, Tawny; Bryant, John W.; Leonard, Daniele; Bolton, Gary; Narasimhan, Lakshmi; Zhang, Erli; Peterson, J. Thomas; Haarer, Staci; Sahasrabudhe, Vaishali; Janiczek, Nancy; Desiraju, Shrilakshmi; Hena, Mostofa; Fiakpui, Charles; Saraswat, Neerja; Sharma, Raman; Sun, Shaoyi; Maiti, Samarendra N.; Leadley, Robert; Edmunds, Jeremy J.

CORPORATE SOURCE: Michigan Labs, Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA

SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(13), 4379-4392

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:95784


IT 675834-30-7 896420-90-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(glycine and related amino acid-based factor Xa inhibitors)


RN 675834-30-7 CAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methoxyethyl)amino]-N-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 896420-90-9 CAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](cyclopropylmethyl)amino]-N-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1081019 CAPLUS

DOCUMENT NUMBER: 142:38528

TITLE: Preparation of 1,1-disubstituted cycloalkyl-, glycinamidyl-, sulfonylamidino-, and tetrahydropyrimidinyl-containing diaminoalkanes and  $\beta$ - or  $\alpha$ -amino acids and their derivatives as factor Xa inhibitors

INVENTOR(S): Qiao, Jennifer X.; Pinto, Donald J.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108892	A2	20041216	WO 2004-US17296	20040602
WO 2004108892	A3	20050217		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040266761	A1	20041230	US 2004-858084	20040601
US 7250415	B2	20070731		
EP 1628668	A2	20060301	EP 2004-754003	20040602
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2006526653	T	20061124	JP 2006-515071	20040602
PRIORITY APPLN. INFO.:			US 2003-475731P	P 20030604
			WO 2004-US17296	W 20040602

OTHER SOURCE(S): MARPAT 142:38528



IT 1083065-50-2  
 RL: PRPH (Prophetic)  
 (Preparation of 1,1-disubstituted cycloalkyl-, glycinamidyl-,  
 sulfonylamidino-, and tetrahydropyrimidinyl-containing diaminoalkanes  
 and  $\beta$ - or  $\alpha$ -amino acids and their derivatives as factor Xa  
 inhibitors)  
 RN 1083065-50-2 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED




L3 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:738402 CAPLUS  
 DOCUMENT NUMBER: 141:243828  
 TITLE: Synthesis of amino acid ethylene derivatives for use  
 as coagulation factor Xa inhibitors for treatment of  
 disease  
 INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch,  
 Dieter; Cezanne, Bertram; Gleitz, Johannes; Van  
 Amsterdam, Christoph  
 PATENT ASSIGNEE(S): Merck Patent GmbH, Germany  
 SOURCE: Ger. Offen., 19 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10308907	A1	20040909	DE 2003-10308907	20030228
AU 2004215708	A1	20040910	AU 2004-215708	20040130
CA 2517391	A1	20040910	CA 2004-2517391	20040130
WO 2004076429	A1	20040910	WO 2004-EP817	20040130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1597244	A1	20051123	EP 2004-706669	20040130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007865	A	20060301	BR 2004-7865	20040130
CN 1753882	A	20060329	CN 2004-80005443	20040130
JP 2006519188	T	20060824	JP 2006-501655	20040130
MX 2005PA09002	A	20051018	MX 2005-PA9002	20050824
US 20060084648	A1	20060420	US 2005-547130	20050826
US 7427618	B2	20080923		
PRIORITY APPLN. INFO.:			DE 2003-10308907	A 20030228
			WO 2004-EP817	W 20040130


OTHER SOURCE(S): MARPAT 141:243828  
 IT 1066553-85-2 1066554-04-8 1066554-08-2  
 1067243-86-0  
 RL: PRPH (Prophetic)  
 (Synthesis of amino acid ethylene derivatives for use as coagulation  
 factor Xa inhibitors for treatment of disease)  
 RN 1066553-85-2 CAPLUS  
 CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-N-[3-fluoro-4-(3-  
 methylene-4-morpholinyl)phenyl]-3-methoxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1066554-04-8 CAPLUS  
 CN Pentanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-N-[3-fluoro-4-(3-  
 oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1066554-08-2 CAPLUS  
 CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-N-[3-fluoro-4-(3-  
 methylene-4-morpholinyl)phenyl]-3-hydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1067243-86-0 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



IT 749250-59-7P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of amino acid ethylene derivs. for use as coagulation factor Xa  
 inhibitors for treatment of disease)  
 RN 749250-59-7 CAPLUS  
 CN Pentanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-N-[4-(3-oxo-4-  
 morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 749250-60-0 749250-61-1 749250-62-2  
749250-64-4


RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(preparation of amino acid ethylene derivs. for use as coagulation factor Xa  
inhibitors for treatment of disease)

RN 749250-60-0 CAPLUS

CN Pentanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-4-methyl-N-[4-(3-  
oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 749250-61-1 CAPLUS

CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-  
ethynylphenyl)amino]carbonyl]amino]-4-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 749250-62-2 CAPLUS

CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-3-methoxy-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 749250-64-4 CAPLUS

CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-3-hydroxy-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 749250-66-6 749250-67-7 749250-68-8


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of amino acid ethylene derivs. for use as coagulation factor Xa inhibitors for treatment of disease)

RN 749250-66-6 CAPLUS

CN Pentanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-N-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 749250-67-7 CAPLUS

CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-3-methoxy-N-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 749250-68-8 CAPLUS

CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-3-hydroxy-N-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:605492 CAPLUS

DOCUMENT NUMBER: 141:157122

TITLE: Preparation of ureidoazinyllalkanamides as inhibitors of blood coagulation Factor VIIa and Xa.

INVENTOR(S): Dorsch, Dieter; Cezanne, Bertram; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes; Van Amsterdam, Christoph

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Ger. Offen., 25 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10302500	A1	20040729	DE 2003-10302500	20030123
AU 2004205354	A1	20040805	AU 2004-205354	20040108
CA 2514100	A1	20040805	CA 2004-2514100	20040108
WO 2004065369	A1	20040805	WO 2004-EP61	20040108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
EP 1585730	A1	20051019	EP 2004-700684	20040108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006844	A	20051213	BR 2004-6844	20040108
CN 1741996	A	20060301	CN 2004-80002520	20040108
JP 2006516566	T	20060706	JP 2006-500530	20040108
MX 2005PA07715	A	20050930	MX 2005-PA7715	20050720
US 20060074072	A1	20060406	US 2005-543109	20050722
ZA 2005006730	A	20060531	ZA 2005-6730	20050822
PRIORITY APPLN. INFO.:			DE 2003-10302500	A 20030123
			WO 2004-EP61	A 20040108

OTHER SOURCE(S): MARPAT 141:157122


IT 678178-11-5P 728945-08-2P 728945-09-3P  
 728945-10-6P 728945-11-7P 728945-13-9P  
 728945-14-0P 728945-16-2P 728945-17-3P  
 728945-18-4P 728945-19-5P 728945-20-8P  
 728945-21-9P 728945-22-0P 728945-23-1P  
 728945-24-2P 728945-25-3P 728945-26-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of ureidoazinyllalkanamides as inhibitors of Factor VIIa and Xa)


RN 678178-11-5 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 728945-08-2 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]- (CA INDEX NAME)



RN 728945-09-3 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 728945-10-6 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 728945-11-7 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 728945-13-9 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 728945-14-0 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-(methylsulfonyl)-


N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 728945-16-2 CAPLUS

CN 1-Propanesulfonic acid, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]- (CA INDEX NAME)



RN 728945-17-3 CAPLUS


CN 1-Propanesulfonic acid, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(2-oxo-1(2H)-pyridinyl)phenyl]amino]- (CA INDEX NAME)




RN 728945-18-4 CAPLUS

CN Phosphonic acid, [(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 728945-19-5 CAPLUS  
 CN Phosphonic acid, [2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(2-oxo-1-piperidinyl)phenyl]amino]propyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 728945-20-8 CAPLUS  
 CN Phosphonic acid, [2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 728945-21-9 CAPLUS  
 CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(S-methylsulfonimidoyl)-N-[4-(3-oxo-4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 728945-22-0 CAPLUS

CN Propanamide, 3-(aminosulfonyl)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 728945-23-1 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-[(methylsulfonyl)amino]-N-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 728945-24-2 CAPLUS


CN Propanamide, 3-[(aminosulfonyl)oxy]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 728945-25-3 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-3-(methylsulfonyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 728945-26-4 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl)phenyl]-3-(methylsulfonyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 728945-29-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of ureidoazinyllalkanamides as inhibitors of Factor VIIa and Xa)

RN 728945-29-7 CAPLUS  
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-(methylthio)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.




L3 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:498571 CAPLUS  
DOCUMENT NUMBER: 141:218300  
TITLE: Structure-based design of amidinophenylurea-derivatives for factor VIIa inhibition  
AUTHOR(S): Klingler, Otmar; Matter, Hans; Schudok, Manfred; Donghi, Monica; Czech, Joerg; Lorenz, Martin; Nestler, Hans Peter; Szillat, Hauke; Schreuder, Herman  
CORPORATE SOURCE: Aventis Pharma Deutschland GmbH, Frankfurt, D-65926, Germany  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3715-3720  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier Science B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 141:218300  
IT 745031-07-6P 745031-17-8P 745031-18-9P  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(structure-based design of amidinophenylurea-derivs. for factor VIIa inhibition)  
RN 745031-07-6 CAPLUS  
CN Acetamide, 2-[[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[1-[4-(4-morpholinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 745031-17-8 CAPLUS  
 CN Acetamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[1-[3-bromo-4-(4-morpholinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 745031-18-9 CAPLUS  
 CN Acetamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[1-[4-(4-morpholinyl)-3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:308415 CAPLUS

DOCUMENT NUMBER: 140:321240

TITLE: Preparation of lactam-containing diaminoalkanes,  $\beta$ -amino acids,  $\alpha$ -amino acids and derivatives thereof as factor Xa inhibitors

INVENTOR(S): Qiao, Jennifer X.; Han, Wei

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 172 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031145	A2	20040415	WO 2003-US31079	20031001
WO 2004031145	A3	20040701		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 20040077635 A1 20040422 US 2003-677063 20031001  
 AU 2003279735 A1 20040423 AU 2003-279735 20031001  
 EP 1558606 A2 20050803 EP 2003-773077 20031001  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 US 20070129361 A1 20070607 US 2007-622484 20070112  
 PRIORITY APPLN. INFO.: US 2002-415366P P 20021002  
 US 2002-417208P P 20021009  
 US 2003-677063 A1 20031001  
 WO 2003-US31079 W 20031001

OTHER SOURCE(S): MARPAT 140:321240


IT 678174-81-7P 678177-49-6P 678177-92-9P  
 678177-93-0P 678178-00-2P 678178-01-3P  
 678178-02-4P 678178-03-5P 678178-04-6P  
 678178-05-7P 678178-06-8P 678178-07-9P  
 678178-08-0P 678178-09-1P 678178-10-4P  
 678178-11-5P 678178-18-2P 678178-19-3P  
 678178-20-6P 678178-21-7P 678178-23-9P  
 678178-25-1P 678178-27-3P 678178-29-5P  
 678178-30-8P 678178-31-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of lactam-containing diaminoalkanes,  $\beta$ -amino acids,  
 $\alpha$ -amino acids and derivs. thereof as factor Xa inhibitors for  
 treating thromboembolic disorder)


RN 678174-81-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-  
 oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678177-49-6 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-  
 oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678177-92-9 CAPLUS


CN Benzo[b]thiophene-2-acetamide,  $\alpha$ -[[[(4-  
 chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-  
 (CA INDEX NAME)






RN 678177-93-0 CAPLUS

CN Benzo[b]thiophene-2-acetamide,  $\alpha$ -[[[4-chlorophenyl]amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny]phenyl]- (CA INDEX NAME)




RN 678178-00-2 CAPLUS

CN Pentanamide, 2-[[[4-(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny]phenyl]- (CA INDEX NAME)




RN 678178-01-3 CAPLUS

CN Propanamide, 2-[[[4-(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny]phenyl]- (CA INDEX NAME)




RN 678178-02-4 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny)phenyl]- (CA INDEX NAME)




RN 678178-03-5 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-N-[4-(2-oxo-1-piperidiny)phenyl]- (CA INDEX NAME)




RN 678178-04-6 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny)phenyl]- (CA INDEX NAME)




RN 678178-05-7 CAPLUS

CN Benzenebutamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny)phenyl]- (CA INDEX NAME)




RN 678178-06-8 CAPLUS

CN Propanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1-piperidiny)phenyl]- (CA INDEX NAME)




RN 678178-07-9 CAPLUS

CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1-piperidiny)phenyl]- (CA INDEX NAME)




RN 678178-08-0 CAPLUS

CN Pentanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1-piperidiny)phenyl]- (CA INDEX NAME)




RN 678178-09-1 CAPLUS

CN Pentanamide, 5-amino-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny)phenyl]- (CA INDEX NAME)




RN 678178-10-4 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methanesulfonyl)-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)




RN 678178-11-5 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methanesulfonyl)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 678178-18-2 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 678178-19-3 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 678178-20-6 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 678178-21-7 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 678178-23-9 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 678178-25-1 CAPLUS

CN Benzenebutanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 678178-27-3 CAPLUS

CN Propanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 678178-29-5 CAPLUS

CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)




RN 678178-30-8 CAPLUS

CN Pentanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-31-9 CAPLUS

CN Pentanamide, 5-amino-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



L3 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:252476 CAPLUS

DOCUMENT NUMBER: 140:287179

TITLE: Preparation of  
[phenylureido(hetero)cyclyl]carboxamides as inhibitors  
of factor Xa and other serine proteases involved in  
the coagulation cascade

INVENTOR(S): Bolton, Gary Louis; Filipski, Kevin James; Kohrt,  
Jeffrey Thomas; La, Frances Thu; Leonard, Daniele  
Marie

PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA

SOURCE: PCT Int. Appl., 111 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024679	A1	20040325	WO 2003-IB3900	20030902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2497003	A1	20040325	CA 2003-2497003	20030902
AU 2003260821	A1	20040430	AU 2003-260821	20030902
EP 1539686	A1	20050615	EP 2003-795154	20030902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014219	A	20050719	BR 2003-14219	20030902
JP 2005538175	T	20051215	JP 2004-535772	20030902
US 20040167131	A1	20040826	US 2003-662046	20030911
MX 2005PA02703	A	20050505	MX 2005-PA2703	20050310
PRIORITY APPLN. INFO.:			US 2002-409891P	P 20020911
			WO 2003-IB3900	W 20030902


OTHER SOURCE(S): MARPAT 140:287179

IT 675834-30-7P, 2-[3-(4-Chlorophenyl)-1-(2-methoxyethyl)ureido]-N-[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]acetamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(factor Xa inhibitor; preparation of  
[phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for  
treatment of abnormal thrombosis)

RN 675834-30-7 CAPLUS  
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methoxyethyl)amino]-N-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:143100 CAPLUS

DOCUMENT NUMBER: 140:199315

TITLE: Preparation of iminothiazolidinone amino acid derivatives as inhibitors of HCV replication

INVENTOR(S): Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren; Lemm, Julie; O'Boyle, Donald; Gao, Min; Colonno, Richard

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 127 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014852	A2	20040219	WO 2003-US24717	20030808
WO 2004014852	A3	20040422		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003261434	A1	20040225	AU 2003-261434	20030808
US 20050069522	A1	20050331	US 2003-637156	20030808
US 20050096364	A1	20050505	US 2003-637099	20030808
US 7183302	B2	20070227		

PRIORITY APPLN. INFO.:  
US 2002-402661P P 20020812  
US 2002-403694P P 20020815  
WO 2003-US24717 W 20030808

OTHER SOURCE(S): MARPAT 140:199315


IT 657414-06-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of iminothiazolidinone amino acid derivs. as inhibitors of HCV replication)



Absolute stereochemistry.  
Double bond geometry unknown.



L3 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:142910 CAPLUS  
DOCUMENT NUMBER: 140:199742  
TITLE: Preparation of iminothiazolidinone amino acid  
derivatives as combination pharmaceutical agents for  
use as inhibitors of HCV replication  
INVENTOR(S): Colunno, Richard; Lemm, Julie; O'Boyle, Donald; Gao,  
Min; Romine, Jeffrey Lee; Martin, Scott W.; Snyder,  
Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind;  
Whitehouse, Darren  
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
SOURCE: PCT Int. Appl., 129 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014313	A2	20040219	WO 2003-US25036	20030808
WO 2004014313	A3	20051215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003264038	A1	20040225	AU 2003-264038	20030808
US 20050069522	A1	20050331	US 2003-637156	20030808

US 20050096364 A1 20050505 US 2003-637099 20030808  
 US 7183302 B2 20070227  
 PRIORITY APPLN. INFO.: US 2002-402661P P 20020812  
 US 2002-403694P P 20020815  
 WO 2003-US25036 W 20030808

OTHER SOURCE(S): MARPAT 140:199742

IT 657414-06-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of iminothiazolidinone amino acid derivs. as combination pharmaceutical agents for use as inhibitors of HCV replication)

RN 657414-06-7 CAPLUS

CN Propanamide, N-[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]-2-[[ (phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.



L3 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:2850 CAPLUS

DOCUMENT NUMBER: 140:77013

TITLE: Preparation of diphenylazetidinones for the treatment of hyperlipidemia, arteriosclerosis and hypercholesterolemia

INVENTOR(S): Jaehne, Gerhard; Frick, Wendelin; Flohr, Stefanie; Lindenschmidt, Andreas; Glombik, Heiner; Kramer, Werner; Heuer, Hubert; Schaefer, Hans-Ludwig

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000804	A1	20031231	WO 2003-EP5815	20030604
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,  
 TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10227506	A1	20040108	DE 2002-10227506	20020619
CA 2490109	A1	20031231	CA 2003-2490109	20030604
AU 2003242616	A1	20040106	AU 2003-242616	20030604
EP 1517892	A1	20050330	EP 2003-760591	20030604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011940	A	20050405	BR 2003-11940	20030604
CN 1662493	A	20050831	CN 2003-814087	20030604
NZ 537304	A	20051028	NZ 2003-537304	20030604
JP 2005533072	T	20051104	JP 2004-514660	20030604
RU 2315754	C2	20080127	RU 2005-101091	20030604
US 20040082561	A1	20040429	US 2003-463807	20030618
US 7176194	B2	20070213		
MX 2004PA12236	A	20050225	MX 2004-PA12236	20041207
IN 2004CN02826	A	20060210	IN 2004-CN2826	20041214
NO 2005000073	A	20050106	NO 2005-73	20050106
ZA 2004009381	A	20060531	ZA 2004-9831	20060403
US 20060270613	A1	20061130	US 2006-501758	20060810
US 20070037787	A1	20070215	US 2006-544746	20061010
US 7407938	B2	20080805		
US 20070043017	A1	20070222	US 2006-544718	20061010
US 7390790	B2	20080624		

PRIORITY APPLN. INFO.: DE 2002-10227506 A 20020619  
 US 2002-411984P P 20020919  
 WO 2003-EP5815 W 20030604  
 US 2003-463807 A1 20030618


OTHER SOURCE(S): MARPAT 140:77013

IT 640333-25-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (target compound; preparation of diphenylazetidinones for the treatment of  
 hyperlipidemia, arteriosclerosis and hypercholesterolemia)

RN 640333-25-1 CAPLUS  
 CN Acetamide, 2-[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-[3-  
 [3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxo-1-  
 azetidiny]l]phenyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 640333-24-0  
 CMF C36 H37 F N6 O5



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:892749 CAPLUS  
 DOCUMENT NUMBER: 139:381378  
 TITLE: Preparation of carboxylic acid amides as inhibitors of blood-coagulation factor Xa and VIIa  
 INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Gleitz, Johannes; Cezanne, Bertram; Tsaklakidis, Christos; Barnes, Christopher  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 79 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093235	A1	20031113	WO 2003-EP3331	20030331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

DE 10218974	A1	20031127	DE 2002-10218974	20020427
DE 10236868	A1	20040226	DE 2002-10236868	20020812
CA 2483228	A1	20031113	CA 2003-2483228	20030331
AU 2003226755	A1	20031117	AU 2003-226755	20030331
EP 1499591	A1	20050126	EP 2003-747402	20030331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005531547	T	20051020	JP 2004-501374	20030331
US 20050171154	A1	20050804	US 2004-512478	20041026
US 7183277	B2	20070227		

PRIORITY APPLN. INFO.:

DE 2002-10218974	A	20020427
DE 2002-10236868	A	20020812
WO 2003-EP3331	W	20030331

OTHER SOURCE(S): MARPAT 139:381378


IT 625102-16-1P 625102-18-3P 625102-20-7P  
625102-30-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of carboxylic acid amides as inhibitors of blood-coagulation factor Xa and VIIa)

RN 625102-16-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-methyl-4-(2-thioxo-1-pyrrolidinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 625102-18-3 CAPLUS


CN 2H-Pyrrolidium, 1-[4-[[[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-phenylacetyl]amino]-2-methylphenyl]-3,4-dihydro-5-(methylthio)-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.




RN 625102-20-7 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)-3-methylphenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-30-9 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 625102-22-9P 625102-24-1P 625102-26-3P  
 625102-28-5P 625102-32-1P 625102-34-3P  
 625102-36-5P 625102-38-7P 625102-40-1P  
 625102-42-3P 625102-43-4P 625102-46-7P  
 625102-49-0P 625102-64-9P 625102-66-1P  
 625102-67-2P 625102-69-4P 625102-70-7P  
 625102-72-9P 625102-73-0P 625102-75-2P  
 625102-76-3P 625102-78-5P 625102-79-6P  
 625102-81-0P 625102-82-1P 625102-86-5P  
 625102-88-7P 625102-90-1P 625102-91-2P  
 625102-93-4P 625102-94-5P 625102-96-7P  
 625102-97-8P 625102-99-0P 625103-00-6P  
 625103-02-8P 625103-03-9P 625103-05-1P  
 625103-06-2P 625103-08-4P 625103-09-5P  
 625103-11-9P 625103-12-0P 625103-14-2P  
 625103-15-3P 625103-16-4P 625103-17-5P  
 625103-19-7P 625103-20-0P 625103-22-2P  
 625103-23-3P 625103-25-5P 625103-26-6P  
 625103-28-8P 625103-29-9P 625103-31-3P  
 625103-34-6P 625103-36-8P 625103-37-9P  
 625103-39-1P 625103-40-4P 625103-42-6P  
 625103-43-7P 625103-68-6P 625103-70-0P  
 625103-72-2P 625103-74-4P 625103-77-7P  
 625103-80-2P 625103-82-4P 625103-85-7P  
 625103-87-9P 625104-13-4P 625104-18-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of carboxylic acid amides as inhibitors of blood-coagulation  
 factor Xa and VIIa)

RN 625102-22-9 CAPLUS

CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-  
 imino-1-pyrrolidiny)-3-methylphenyl]-, hydrochloride (1:1), (αR)-  
 (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 625102-24-1 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)-3-methylphenyl]-, hydrochloride (1:1), ( $\alpha$ R)-  
 (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 625102-26-3 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(methoxyimino)-1-piperidinyl]-3-methylphenyl]-, ( $\alpha$ S)- (CA INDEX  
 NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.






RN 625102-28-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(methoxyimino)-1-pyrrolidinyl]phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 625102-32-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, hydrochloride (1:1), ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 625102-34-3 CAPLUS  
 CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, hydrochloride (1:1), ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 625102-36-5 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625102-38-7 CAPLUS  
 CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625102-40-1 CAPLUS  
 CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)-3-methylphenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-42-3 CAPLUS  
 CN 2-Thiopheneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625102-43-4 CAPLUS  
 CN 2-Thiopheneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-, ( $\alpha$ R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 625102-42-3  
 CMF C23 H23 Cl N6 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 625102-46-7 CAPLUS  
 CN Benzeneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]- $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-, ( $\alpha$ R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 625102-45-6  
 CMF C25 H25 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 625102-49-0 CAPLUS  
 CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-48-9  
 CMF C22 H27 Cl N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625102-64-9 CAPLUS

CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-chloro-2-methylphenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 625102-66-1 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625102-67-2 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, ( $\alpha$ R)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 625102-66-1  
 CMF C26 H26 Cl N5 O2


Absolute stereochemistry.



CM 2

CRN 87-69-4  
 CMF C4 H6 O6


Absolute stereochemistry.



RN 625102-69-4 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-70-7 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, ( $\alpha$ S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 625102-69-4

CMF C25 H24 Cl N5 O2

Absolute stereochemistry.




CM 2

CRN 147-71-7

CMF C4 H6 O6

Absolute stereochemistry.






RN 625102-72-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-73-0 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, ( $\alpha$ S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 625102-72-9

CMF C26 H26 Cl N5 O2


Absolute stereochemistry.



CM 2


CRN 147-71-7  
CMF C4 H6 O6

Absolute stereochemistry.



RN 625102-75-2 CAPLUS  
CN 2-Thiopheneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-  
 $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-, ( $\alpha$ R)- (CA INDEX  
NAME)

Absolute stereochemistry.




RN 625102-76-3 CAPLUS  
CN 2-Thiopheneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-  
 $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-, ( $\alpha$ R)-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-75-2  
CMF C22 H21 Cl N6 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625102-78-5 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-5-methyl-1,3,4-thiadiazol-3(2H)-yl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-79-6 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-5-methyl-1,3,4-thiadiazol-3(2H)-yl)phenyl]-, ( $\alpha$ R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-78-5

CMF C24 H21 Cl N6 O2 S


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625102-81-0 CAPLUS

CN Benzeneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-  
α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)- (CA INDEX  
NAME)

Absolute stereochemistry.



RN 625102-82-1 CAPLUS


CN Benzeneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-  
α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-81-0

CMF C24 H23 Cl N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625102-86-5 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625102-88-7 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 625102-90-1 CAPLUS

CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-91-2 CAPLUS


CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-90-1

CMF C21 H25 Cl N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625102-93-4 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-94-5 CAPLUS


CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-93-4

CMF C22 H26 Cl N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 625102-96-7 CAPLUS


CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 625102-97-8 CAPLUS  
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)  
CM 1  
CRN 625102-96-7  
CMF C19 H20 Cl N5 O2

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 625102-99-0 CAPLUS  
CN Acetamide, 2-[[[4-chlorophenyl]amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 625103-00-6 CAPLUS  
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
CM 1  
CRN 625102-99-0  
CMF C20 H20 Cl N7 O2

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-02-8 CAPLUS  
CN Propanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625103-03-9 CAPLUS  
 CN Propanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)-, 2,2,2-trifluoroacetate (1:1)  
 (CA INDEX NAME)

CM 1


CRN 625103-02-8  
 CMF C19 H21 Cl N6 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2



RN 625103-05-1 CAPLUS  
 CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 625103-06-2 CAPLUS  
CN Propanamide, 2-[[[4-(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 625103-05-1  
CMF C21 H22 Cl N7 O2

Absolute stereochemistry.  
Double bond geometry unknown.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-08-4 CAPLUS  
 CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625103-09-5 CAPLUS  
 CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 625103-08-4  
 CMF C20 H22 Cl N5 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-11-9 CAPLUS  
CN Butanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625103-12-0 CAPLUS  
CN Butanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-11-9  
CMF C21 H25 Cl N6 O2


Absolute stereochemistry.






CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-14-2 CAPLUS  
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 625103-15-3 CAPLUS  
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-3-methyl-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 625103-14-2  
CMF C23 H26 Cl N7 O2


Absolute stereochemistry.  
Double bond geometry unknown.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625103-16-4 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-17-5 CAPLUS


CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-16-4

CMF C22 H26 Cl N5 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625103-19-7 CAPLUS

CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-20-0 CAPLUS

CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-


chlorophenyl)amino]carbonyl]amino]-4-methyl-, (2R)-,  
2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-19-7

CMF C22 H27 Cl N6 O2


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 625103-22-2 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 625103-23-3 CAPLUS  
 CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-4-methyl-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 625103-22-2  
 CMF C24 H28 Cl N7 O2

Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 625103-25-5 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-26-6 CAPLUS


CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-4-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-25-5


CMF C23 H28 Cl N5 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 625103-28-8 CAPLUS  
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 625103-29-9 CAPLUS  
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 625103-28-8

CMF C21 H24 Cl N5 O3

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1


CMF C2 H F3 O2






RN 625103-31-3 CAPLUS  
 CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-3-methoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 625103-34-6 CAPLUS  
 CN 1H-Imidazole-4-propanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-1-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 625103-33-5  
 CMF C24 H24 Cl N9 O2

PAGE 1-A




PAGE 2-A




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 625103-36-8 CAPLUS  
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(5-ethyl-2-imino-1,3,4-thiadiazol-3(2H)-yl)phenyl]-3-methoxy- (CA INDEX NAME)




RN 625103-37-9 CAPLUS

CN Propanamide, 2-[[[4-(5-ethyl-2-imino-1,3,4-thiadiazol-3(2H)-yl)phenyl]-3-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-36-8


CMF C21 H23 Cl N6 O3 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 625103-39-1 CAPLUS


CN 1,3,4-Thiadiazole-2-carboxamide, 4-[4-[[2-[[[4-(5-ethyl-2-imino-1,3,4-thiadiazol-3(2H)-yl)phenyl]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino- (CA INDEX NAME)



RN 625103-40-4 CAPLUS  
 CN 1,3,4-Thiadiazole-2-carboxamide, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 625103-39-1  
 CMF C20 H20 Cl N7 O4 S




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 625103-42-6 CAPLUS  
 CN 1,3,4-Thiadiazole-2-carboxylic acid, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino-, ethyl ester (CA INDEX NAME)



RN 625103-43-7 CAPLUS  
 CN 1,3,4-Thiadiazole-2-carboxylic acid, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino-, ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 625103-42-6  
 CMF C22 H23 Cl N6 O5 S



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 625103-68-6 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 625103-70-0 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(2-imino-1-piperidinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 625103-72-2 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidiny)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 625103-74-4 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(2-imino-1-pyrrolidiny)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625103-77-7 CAPLUS  
 CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidiny]phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625103-80-2 CAPLUS  
 CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidiny]phenyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.



RN 625103-82-4 CAPLUS  
 CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidiny]phenyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry unknown.



RN 625103-85-7 CAPLUS

CN Benzeneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 625103-87-9 CAPLUS

CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 625104-13-4 CAPLUS


CN 1H-Imidazole-4-propanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-1-methyl-, ( $\alpha R$ )- (CA INDEX NAME)

Absolute stereochemistry.



RN 625104-18-9 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-4-(methylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:376636 CAPLUS  
 DOCUMENT NUMBER: 138:385436  
 TITLE: Preparation of  
 4-(1,1-dioxido-2-isothiazolidinyl)benzenamines as  
 inhibitors of blood-coagulation factor Xa for the  
 treatment of thromboembolic diseases  
 INVENTOR(S): Dorsch, Dieter; Cezanne, Bertram; Tsaklakidis,  
 Christos; Mederski, Werner; Gleitz, Johannes; Barnes,  
 Christopher  
 PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany  
 SOURCE: PCT Int. Appl., 81 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039543	A1	20030515	WO 2002-EP11349	20021010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10155075	A1	20030522	DE 2001-10155075	20011109
CA 2465713	A1	20030515	CA 2002-2465713	20021010
AU 2002363366	A1	20030519	AU 2002-363366	20021010
AU 2002363366	B2	20071122		
EP 1441726	A1	20040804	EP 2002-802623	20021010
EP 1441726	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013680	A	20041026	BR 2002-13680	20021010
HU 2004001983	A2	20050128	HU 2004-1983	20021010
CN 1582148	A	20050216	CN 2002-821919	20021010
JP 2005522412	T	20050728	JP 2003-541834	20021010
AT 348611	T	20070115	AT 2002-802623	20021010
RU 2301228	C2	20070620	RU 2004-117594	20021010
ES 2277623	T3	20070716	ES 2002-802623	20021010
MX 2004PA04307	A	20040811	MX 2004-PA4307	20040506
US 20040254175	A1	20041216	US 2004-495254	20040510
US 7199133	B2	20070403		
ZA 2004004549	A	20050204	ZA 2004-4549	20040608
PRIORITY APPLN. INFO.:			DE 2001-10155075	A 20011109
			WO 2002-EP11349	W 20021010

OTHER SOURCE(S): MARPAT 138:385436

IT 524957-17-3P 524957-18-4P 524957-19-5P  
 524957-38-8P 524957-39-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(drug candidate; preparation of isothiazolidinylbenzenamines as inhibitors  
 of blood coagulation factor Xa for the treatment of thromboembolic  
 diseases)

RN 524957-17-3 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-

(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 524957-18-4 CAPLUS  
CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 524957-19-5 CAPLUS  
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 524957-38-8 CAPLUS  
CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 524957-39-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:465965 CAPLUS

DOCUMENT NUMBER: 137:47128

TITLE: Preparation of of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders and tumors.

INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Cezanne, Bertram; Gleitz, Johannes; Barnes, Christopher

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----	-----
WO 2002048099	A1	20020620	WO 2001-EP13545	20011121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10063008	A1	20020620	DE 2000-10063008	20001216
CA 2431766	A1	20020620	CA 2001-2431766	20011121
AU 2002021881	A	20020624	AU 2002-21881	20011121
EP 1341755	A1	20030910	EP 2001-270524	20011121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016115	A	20031223	BR 2001-16115	20011121
HU 2003003296	A2	20040128	HU 2003-3296	20011121
HU 2003003296	A3	20060428		
JP 2004515538	T	20040527	JP 2002-549632	20011121
NO 2003002695	A	20030613	NO 2003-2695	20030613
MX 2003PA05342	A	20031006	MX 2003-PA5342	20030613
US 20040038858	A1	20040226	US 2003-450651	20030616
IN 2003KN00896	A	20050311	IN 2003-KN896	20030714
ZA 2003005455	A	20040826	ZA 2003-5455	20030715
US 20050137230	A1	20050623	US 2005-59655	20050217
PRIORITY APPLN. INFO.:			DE 2000-10063008	A 20001216
			WO 2001-EP13545	W 20011121
			US 2003-450651	A3 20030616

OTHER SOURCE(S):                   MARPAT 137:47128

IT   438054-04-7P 438054-05-8P 438054-06-9P  
438054-07-0P 438054-08-1P 438054-09-2P  
438054-10-5P 438054-11-6P 438054-12-7P  
438054-61-6P 438054-62-7P 438054-63-8P  
438054-76-3P 438054-77-4P 438054-78-5P  
438054-79-6P 438054-80-9P 438054-99-0P  
438055-00-6P 438055-01-7P 438055-02-8P  
438055-60-8P 438055-63-1P 438055-65-3P  
438055-66-4P 438055-67-5P 438055-68-6P  
438055-70-0P 438055-71-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders such as strokes and cancer)

RN   438054-04-7   CAPLUS


CN   Benzenepropanamide, N-[4-(4-morpholinyl)phenyl]- $\alpha$ -  
[[ (phenylamino)carbonyl]amino]-, ( $\alpha$ S)-   (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-05-8 CAPLUS


CN Pentanamide, N-[4-(4-morpholinyl)phenyl]-2-[[ (phenylamino)carbonyl]amino]-  
(CA INDEX NAME)



RN 438054-06-9 CAPLUS

CN Benzenepropanamide, N-[4-(4-morpholinyl)phenyl]-α-  
[[ (phenylamino)carbonyl]amino]-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-07-0 CAPLUS


CN Benzenepropanamide, 3-cyano-N-[4-(4-morpholinyl)phenyl]-α-  
[[ (phenylamino)carbonyl]amino]- (CA INDEX NAME)






RN 438054-08-1 CAPLUS

CN Hexanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 438054-09-2 CAPLUS


CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylthio)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 438054-10-5 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438054-11-6 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[4-(4-

morpholinyl)phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-12-7 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[4-(4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-61-6 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-62-7 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]-, ( $\alpha S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-63-8 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(3-oxo-4-morpholinyl)phenyl]-, ( $\alpha R$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-76-3 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-77-4 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-78-5 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperidinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-79-6 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperidinyl)phenyl]-, ( $\alpha S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-80-9 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperidinyl)phenyl]-, ( $\alpha S$ )- (CA INDEX NAME)


Absolute stereochemistry.



RN 438054-99-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[ (2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 438055-00-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[ (2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 438055-01-7 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438055-02-8 CAPLUS


CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, ( $\alpha S$ )- (CA INDEX NAME)

Absolute stereochemistry.




RN 438055-60-8 CAPLUS

CN Benzenepropanamide, 4-cyano-N-[4-(2-oxo-1-piperidiny)phenyl]- $\alpha$ -[[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)




RN 438055-63-1 CAPLUS

CN Benzenepropanamide, 3-(aminocarbonyl)-N-[4-(2-oxo-1-piperidiny)phenyl]- $\alpha$ -[[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)




RN 438055-65-3 CAPLUS  
 CN Benzenepropanamide, 3-(aminocarbonyl)-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny)phenyl]- (CA INDEX NAME)



RN 438055-66-4 CAPLUS  
 CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidiny)phenyl]-, (αR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 438055-67-5 CAPLUS  
 CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-methyl-4-(2-oxo-1-piperidiny)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.






RN 438055-68-6 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperazinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 438055-70-0 CAPLUS

CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 438055-71-1 CAPLUS

CN 2-Thiopheneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]- (CA INDEX NAME)



IT 438055-87-9P 438055-88-0P 438055-89-1P  
438055-90-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders such as strokes and cancer)

RN 438055-87-9 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 438055-88-0 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[4-[[[(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 438055-89-1 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, hydrochloride (1:?), ( $\alpha$ R)- (CA INDEX NAME)

Absolute stereochemistry.




●<sub>x</sub> HCl

RN 438055-90-4 CAPLUS

CN Benzenepropanamide,  $\alpha$ -[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, hydrochloride (1:?), ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626


PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	3	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	4	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	5	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	6	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	7	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS	8	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	9	NOV 26	MARPAT enhanced with FSORT command
NEWS	10	NOV 26	MEDLINE year-end processing temporarily halts availability of new fully-indexed citations
NEWS	11	NOV 26	CHEMSAFE now available on STN Easy
NEWS	12	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	13	DEC 01	ChemPort single article sales feature unavailable

```
=>
Uploading C:\Program Files\STNEXP\Queries\10543109d.str
```



```

chain nodes :
7 8 9 10 11 12 13 14 15 24
ring nodes :
1 2 3 4 5 6 16 19 20 21 22 23
chain bonds :
5-7 7-8 8-9 8-10 9-11 11-12 12-13 12-15 13-14 14-16 21-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-19 16-23 19-20 20-21 21-22 22-23
exact/norm bonds :
5-7 7-8 8-9 8-10 9-11 12-13 12-15 13-14 21-24
exact bonds :
11-12 14-16
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-19 16-23 19-20 20-21 21-22 22-23

```

```


Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom

```

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\STNEXP\Queries\10543109e.str



```

chain nodes :
7 8 9 10 11 12 13 14 15 24
ring nodes :
1 2 3 4 5 6 16 19 20 21 22 23
chain bonds :
5-7 7-8 8-9 8-10 9-11 11-12 12-13 12-15 13-14 14-16 21-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-19 16-23 19-20 20-21 21-22 22-23
exact/norm bonds :

```

5-7 7-8 8-9 8-10 9-11 12-13 12-15 13-14 21-24

exact bonds :

11-12 14-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-19 16-23 19-20 20-21 21-22 22-23

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS


11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 19:Atom 20:Atom

21:Atom 22:Atom 23:Atom 24:Atom

L2 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\STNEXP\Queries\10543109f.str



chain nodes :

7 8 9 10 11 12 13 14 15 24

ring nodes :

1 2 3 4 5 6 16 19 20 21 22 23

chain bonds :

5-7 7-8 8-9 8-10 9-11 11-12 12-13 12-15 13-14 14-16 21-24

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-19 16-23 19-20 20-21 21-22 22-23

exact/norm bonds :

5-7 7-8 8-9 8-10 9-11 12-13 12-15 13-14 21-24

exact bonds :

11-12 14-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 16-19 16-23 19-20 20-21 21-22 22-23

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 19:Atom 20:Atom

21:Atom 22:Atom 23:Atom 24:Atom

L3 STRUCTURE UPLOADED

=> s l1 sss full

FULL SEARCH INITIATED 13:33:17 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1544 TO ITERATE

100.0% PROCESSED 1544 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.01

L4 21 SEA SSS FUL L1

=> s l2 sss full

FULL SEARCH INITIATED 13:33:20 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL L2

=> s l3 sss full

FULL SEARCH INITIATED 13:33:24 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L3

=> file capl

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

534.16

534.37

FILE 'CAPLUS' ENTERED AT 13:33:26 ON 23 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Dec 2008 VOL 149 ISS 26

FILE LAST UPDATED: 22 Dec 2008 (20081222/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l4

L7 3 L4

=> d l7 1-3 ibib hitstr


L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:175662 CAPLUS

DOCUMENT NUMBER: 148:443897




TITLE: Fluorescence detection of amino acids in the postcleavage conversions for manual sequencing of a peptide  
 AUTHOR(S): Wainaina, Moses N.; Shibata, Takayuki; Smanmoo, Chaivat; Kabashima, Tsutomu; Kai, Masaaki  
 CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, 852-8521, Japan  
 SOURCE: Analytical Biochemistry (2008), 374(2), 423-425  
 CODEN: ANBCA2; ISSN: 0003-2697  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 IT 1019329-90-8 1019329-91-9 1019329-92-0  
 1019329-93-1 1019329-94-2 1019329-97-5  
 1019329-98-6 1019329-99-7 1019330-00-7  
 1019330-03-0 1019330-04-1 1019330-05-2  
 RL: ANT (Analyte); ANST (Analytical study)  
 (fluorescence detection of amino acids in postcleavage conversions for manual sequencing of peptide)  
 RN 1019329-90-8 CAPLUS  
 CN Acetamide, N-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-2-[[ (phenylamino)thioxomethyl]amino]- (CA INDEX NAME)




RN 1019329-91-9 CAPLUS  
 CN Butanamide, N-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-3-methyl-2-[[ (phenylamino)thioxomethyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1019329-92-0 CAPLUS  
 CN Propanamide, N-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-3-hydroxy-2-[[ (phenylamino)thioxomethyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1019329-93-1 CAPLUS

CN Pentanoic acid, 5-[[4-(1-cyano-2H-isoindol-2-yl)phenyl]amino]-5-oxo-4-[[[(phenylamino)thioxomethyl]amino]-, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1019329-94-2 CAPLUS

CN Pentanamide, N-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-3-methyl-2-[[[(phenylamino)thioxomethyl]amino]-, (2S,3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1019329-97-5 CAPLUS


CN Pentanediamide, N1-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-2-[[[(phenylamino)thioxomethyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1019329-98-6 CAPLUS  
 CN Butanediamide, N1-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-2-  
 [[[(phenylamino)thioxomethyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1019329-99-7 CAPLUS  
 CN Butanoic acid, 4-[4-(1-cyano-2H-isoindol-2-yl)phenyl]amino]-4-oxo-3-  
 [[[(phenylamino)thioxomethyl]amino]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1019330-00-7 CAPLUS  
 CN Butanamide, N-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-3-hydroxy-2-  
 [[[(phenylamino)thioxomethyl]amino]-, (2S,3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1019330-03-0 CAPLUS

CN Propanamide, N-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-3-mercapto-2-[[[(phenylamino)thioxomethyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1019330-04-1 CAPLUS

CN Benzenepropanamide, N-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-4-hydroxy-α-[[[(phenylamino)thioxomethyl]amino]-, (αS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1019330-05-2 CAPLUS

CN 1H-Imidazole-5-propanamide, N-[4-(1-cyano-2H-isoindol-2-yl)phenyl]-α-[[[(phenylamino)thioxomethyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:578214 CAPLUS

DOCUMENT NUMBER: 145:63144

TITLE: Preparation of amino acid thiourea derivatives as factor Xa inhibitors

INVENTOR(S): Song, Yonghong; Zhu, Bing-Yan; Bhakta, Chhaya; Scarborough, Robert M.

PATENT ASSIGNEE(S): Portola Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063293	A2	20060615	WO 2005-US44739	20051207
WO 2006063293	A3	20070712		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

US 20060160790 A1 20060720 US 2005-298296 20051207

PRIORITY APPLN. INFO.: US 2004-634150P P 20041207

OTHER SOURCE(S): MARPAT 145:63144


IT 890523-87-2P 890523-94-1P 890524-09-1P  
890524-10-4P 890524-19-3P 890524-20-6P  
890524-21-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amino acid thiourea derivs. as factor Xa inhibitors)


RN 890523-87-2 CAPLUS

CN Acetamide, N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-[[[(2-methyl-5-benzofuranyl)amino]thioxomethyl]amino]- (CA INDEX NAME)



RN 890523-94-1 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-bromophenyl)amino]thioxomethyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 890524-09-1 CAPLUS


CN Butanamide, 2-[[[(4-chlorophenyl)amino]thioxomethyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-3-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 890524-10-4 CAPLUS


CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]thioxomethyl]amino]-N-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 890524-19-3 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]thioxomethyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 890524-20-6 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]thioxomethyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 890524-21-7 CAPLUS

CN Benzeneacetamide,  $\alpha$ -[[[(4-chlorophenyl)amino]thioxomethyl]amino]-N-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, ( $\alpha$ R)- (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:472228 CAPLUS  
 DOCUMENT NUMBER: 115:72228  
 ORIGINAL REFERENCE NO.: 115:12511a,12514a  
 TITLE: Preparation of fluorescent amino acid derivatives  
 INVENTOR(S): Takahashi, Shotaro  
 PATENT ASSIGNEE(S): Seiko Instruments and Electronics, Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 2 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03068551	A	19910325	JP 1989-207221	19890809
PRIORITY APPLN. INFO.:			JP 1989-207221	19890809
OTHER SOURCE(S):		CASREACT 115:72228; MARPAT 115:72228		
IT 135261-44-8P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN 135261-44-8 CAPLUS				
CN Benzoic acid, 2-(3,6-dihydroxy-9H-xanthen-9-yl)-5-[[1-oxo-2-[[[(phenylamino)thioxomethyl]amino]propyl]amino]- (CA INDEX NAME)				





$\Rightarrow$